October 31, 2022
A putative class of direct HIV medication buyers asked a California federal judge to give final approval to a $10.8 million deal that would end claims that Bristol-Myers Squibb engaged in anti-competitive conduct to block generics competition and keep the medication's prices artificially high.
June 06, 2022
A California federal judge gave his blessing Friday to a $10.8 million settlement resolving direct buyers' claims alleging Bristol-Myers Squibb engaged in anti-competitive conduct to block generics competition and keep HIV medication prices artificially high.
February 11, 2021
Gilead Sciences and Bristol-Myers Squibb urged a California federal judge Thursday to nix direct buyers' claims alleging the pharmaceutical companies engaged in anti-competitive conduct to block generic competition and keep HIV medication prices artificially high, arguing the suits should be sent to arbitration or thrown out as time-barred.
October 07, 2020
Gilead Sciences Inc. schemed to monopolize the market for drugs commonly used to treat HIV and forced direct buyers to overpay for the medications as a result, a new proposed class action lawsuit alleges.